 CAMBRIDGE, Mass., March 25, 2021 GLOBE NEWSWIRE -- Solid Biosciences Inc. Nasdaq: SLDB, a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy Duchenne, today announced that Carl Morris, Ph.D., Chief Scientific Officer, will participate in a panel discussion at the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day. The panel entitled The more we learn the less we know about DMDFrom micro-dystrophin, to morpholinos, and small molecules will be held on Thursday, April 1, 2021 from 9:00 a.m. - 9:50 a.m. Eastern Time. 